Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : Sell rating from JP Morgan

12/03/2021 | 06:30am EST

Richard Vosser from JP Morgan retains his negative opinion on the stock with a Sell rating. The target price is still set at CHF 80.


ę MarketScreener with dpa-AFX Analyser 2021
All news about NOVARTIS AG
01/25Merus Regains Worldwide Rights to MCLA-145 After Incyte Opt-Out; Names Chief Commercial..
MT
01/25NOVARTIS AG : Goldman Sachs gives a Buy rating
MD
01/25AlphaValue/Baader Europe Lowers Price Target on Novartis, Upgrades Recommendation to Bu..
MT
01/24NOVARTIS : 2021 Global Managed Access Program Community Update
PU
01/20BAUSCH HEALTH BRIEF : He Will join Bausch + Lomb from Allergan/AbbVie; Prior to that, he w..
MT
01/20NOVARTIS AG : JP Morgan keeps a Sell rating
MD
01/20"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
AQ
01/18Novartis CEO Expects Worldwide Normalcy to COVID-19 By 2022-End
MT
01/18GLOBAL MARKETS LIVE : Toyota, Microsoft, Goldman Sachs, Alibaba, Boeing...
01/18Molecular Partners Shares Drop 14% After Novartis Deal
DJ
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 967 M - -
Net income 2021 24 208 M - -
Net Debt 2021 8 126 M - -
P/E ratio 2021 7,73x
Yield 2021 3,90%
Capitalization 188 B 188 B -
EV / Sales 2021 3,78x
EV / Sales 2022 3,64x
Nbr of Employees 108 000
Free-Float -
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 84,11 $
Average target price 98,49 $
Spread / Average Target 17,1%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-4.40%187 626
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963